title: Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
abstract: The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34(+) cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34(+) cells. The numbers of MC progenitors assayed from MPN CD34(+) cells were, however, similar to that assayed from normal CD34(+) cells. A higher percentage of the cultured MPN MCs expressed FcvarepsilonRIalpha, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F-positive MC colonies were assayable from the PB CD34(+) cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, New York, NY 10029-6574, USA.
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: T
authors.initials: T
authors.lastname: Ishii
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Sozer
authors.forename: Y
authors.initials: Y
authors.lastname: Dai
authors.forename: J
authors.initials: J
authors.lastname: Mascarenhas
authors.forename: V
authors.initials: V
authors.lastname: Najfeld
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Zhao
authors.forename: R
authors.initials: R
authors.lastname: Hoffman
authors.forename: N
authors.initials: N
authors.lastname: Wisch
authors.forename: M
authors.initials: M
authors.lastname: Xu
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D002478:Cells, Cultured; D000069347:Erlotinib Hydrochloride; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D008407:Mast Cells / Q000502:physiology*; D009154:Mutation; D011087:Polycythemia Vera / Q000235:genetics / Q000473:pathology*; D055728:Primary Myelofibrosis / Q000235:genetics / Q000473:pathology*; D011799:Quinazolines / Q000494:pharmacology; D053628:Receptors, Thrombopoietin / Q000235:genetics; D013920:Thrombocythemia, Essential / Q000235:genetics / Q000473:pathology*
chemical_list: D018952:Antigens, CD34; D011799:Quinazolines; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D000069347:Erlotinib Hydrochloride; C507924:JAK2 protein, human; D053614:Janus Kinase 2